VRTX P&L Curve
Vertex Pharmaceuticals Incorporated (VRTX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $124.70B, listed on NASDAQ, employing roughly 6,100 people, carrying a beta of 0.31 to the broader market. Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). Led by Reshma Kewalramani, public since 1991-07-24.
A profit/loss curve charts the theoretical gain or loss of an options position across a range of underlying prices. It helps traders visualize risk, identify breakeven points, and compare strategies before committing capital.
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $124.70B
- Employees
- 6.1K
- IPO Date
- 1991-07-24
- CEO
- Reshma Kewalramani
- Beta
- 0.31
At the current $495.96 spot price with 28.9% ATM implied volatility and 31 days to the front expiration, an at-the-money long straddle carries an approximate combined premium near $33.46, producing breakevens at roughly $462.50 and $529.42. Market-implied 1-standard-deviation range extends from $454.82 to $537.10, which sets the relevant P&L evaluation window for most near-term strategies. Payoff diagrams should be rebuilt from the live options chain; the preceding values are illustrative and assume a single at-the-money straddle for reference.
Frequently asked VRTX pl curve questions
- What does a VRTX ATM straddle cost today?
- Using current VRTX pricing (28.9% ATM IV, 31-day front expiration, $495.96 spot), an at-the-money long straddle (long call + long put at the same strike) carries an approximate combined premium near $33.46 per spread. Breakevens land at roughly $529.42 on the upside and $462.50 on the downside. The estimate uses the Brenner-Subrahmanyam approximation for at-the-money options under Black-Scholes.
- How do I read an options P&L curve?
- An options P&L curve plots theoretical position value at expiration (or at any chosen evaluation date) against the underlying price. The X-axis is the underlying price scenario, the Y-axis is position dollar P&L. The shape of the curve tells you the strategy's directional sensitivity, breakeven points, maximum profit and loss levels, and where time decay or volatility shifts will be most impactful. Multi-leg structures combine the curves of the individual legs to produce composite payoff diagrams.
- What's the difference between a P&L curve and a payoff diagram?
- Strictly: a payoff diagram shows option value at expiration (no time premium left), while a P&L curve typically shows position value at any evaluation date (with remaining time premium). The expiration payoff diagram has kinks at the strikes; the early P&L curve is smooth. For directional-vega trades, the early P&L curve also responds to IV shifts that the expiration payoff diagram does not capture - which is why options traders often look at both views.
- Why are illustrative VRTX P&L numbers approximate?
- The numbers above use Black-Scholes assumptions (lognormal returns, constant volatility, no early exercise, no dividends). Real-world option prices reflect skew, term structure, jump risk, and (for US-style options) early exercise premium. Use the live options chain for actual quoted bid/ask prices when sizing trades; the values here illustrate magnitude only.